The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
Desmond CurranSean MatthewsEliazar Sabater CabreraSilvia Narejos PérezLina Pérez BrevaMika RämetLaura HelmanDae Won ParkTino F SchwarzIsabel Maria Galan MelendezAxel SchaeferNathalie RoyBrigitte StephanDaniel MolnarLusine KostanyanJohn H PowersVeronica HulstrømPublished in: Influenza and other respiratory viruses (2024)
The RSVPreF3 OA vaccine, in addition to preventing infection, attenuated the severity of RSV-associated symptoms in breakthrough infections, with trends of reduced impact on PF and health utility.